Literature DB >> 8137471

Surgical treatment of hepatocellular carcinoma.

Y Kawarada1, F Ito, H Sakurai, K Tanigawa, M Iwata, T Imai, H Yokoi, T Noguchi, R Mizumoto.   

Abstract

The effect of surgical treatment for hepatocellular carcinoma (HCC) was evaluated in 149 resected cases, 83.2% of which were associated with liver cirrhosis. The 3- and 5-year survival rates were 60.1% and 39.4%, respectively. The mortality rate was 4.1%. In patients aged over 70 years, liver cirrhosis was found in 53.3% of cases and the mortality rate was 6.7%. The 3- and 5-year survival rates were 50.8% and 33.9%, respectively. Factors that significantly affected survival for more than 5 years were a tumor size of less than 3 cm, Stage I disease, vp(-), IMo, and diploid type. The 5-year survival rate for patients with a single tumor of 3 cm or less was 54.2%, regardless of the surgical procedure. All 15 patients with a solitary tumor of 2 cm or less (Stage I, small liver tumor) were alive with a 5-year survival rate of 100%. The problem is the treatment of patients with a tumor measuring 3-5 cm in diameter and associated liver cirrhosis, because their prognosis after surgery is the worst. HrS (subsegmentectomy) is the minimal procedure of limited hepatectomy for these cases with postoperative multidisciplinary therapy.

Entities:  

Mesh:

Year:  1994        PMID: 8137471     DOI: 10.1007/bf00686661

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

Review 1.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

2.  Postoperative recurrence of hepatocellular carcinoma.

Authors:  T Nagao; S Inoue; F Yoshimi; M Sodeyama; Y Omori; T Mizuta; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

3.  Preoperative estimation of operative risk in liver surgery, with special reference to functional reserve of the remnant liver following major hepatic resection.

Authors:  R Mizumoto; Y Kawarada; T Noguchi
Journal:  Jpn J Surg       Date:  1979-12

4.  Significance of glucose tolerance as prognostic sign in hepatectomized patients.

Authors:  K Ozawa; T Ida; T Yamada; I Honjo
Journal:  Am J Surg       Date:  1976-05       Impact factor: 2.565

5.  Significance of multidisciplinary therapy for hepatocellular carcinoma.

Authors:  Y Kawarada; T Imai; M Iwata; H Yokoi; T Noguchi; R Mizumoto
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  A multiple regression equation for prediction of posthepatectomy liver failure.

Authors:  N Yamanaka; E Okamoto; K Kuwata; N Tanaka
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

7.  Hepatic resection for 28 patients with small hepatocellular carcinoma.

Authors:  M F Chen; T L Hwang; L B Jeng
Journal:  Int Surg       Date:  1992 Apr-Jun

8.  Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer.

Authors:  T Kanematsu; K Takenaka; T Matsumata; T Furuta; K Sugimachi; K Inokuchi
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

Review 9.  The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan.

Authors: 
Journal:  Jpn J Surg       Date:  1989-01
  9 in total
  3 in total

Review 1.  Quality of complication reporting in the surgical literature.

Authors:  Robert C G Martin; Murray F Brennan; David P Jaques
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

Review 2.  Practical considerations in the treatment of hepatocellular carcinoma.

Authors:  M Colleoni; R A Audisio; F De Braud; N Fazio; G Martinelli; A Goldhirsch
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

3.  Role of liver transplantation in the treatment of unresectable liver cancer.

Authors:  R Pichlmayr; A Weimann; K J Oldhafer; H J Schlitt; J Klempnauer; A Bornscheuer; A Chavan; E Schmoll; H Lang; G Tusch
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.